Mitragyna Speciosa Alkaloids: HER2 Breast Cancer Inhibitors

the following text:

Unlocking HER2-Positive Breast Cancer Treatment: kratom-Derived Compounds Show Promise

HER2-positive breast cancer, representing approximately 20% of all breast cancer diagnoses worldwide, has historically been associated with aggressive disease and poorer ‌prognoses. While therapies like trastuzumab (Herceptin) and pertuzumab (Perjeta) have revolutionized treatment outcomes, challenges with drug resistance and harmful side effects remain. This drives the need for novel therapeutic approaches.

Now, researchers are⁢ re-examining natural products as a source of drug finding.⁣ A new study published in Current Research in Structural Biology explores the anti-HER2 effects of two​ alkaloids derived from Mitragyna speciosa (kratom): mitragynine and 7-hydroxymitragynine (7-OH). Using molecular docking, molecular dynamics simulations,‌ and absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiling, investigators ⁣assessed these potential effects.

The study revealed that both mitragynine ​and ​7-OH demonstrated stable binding affinity with the HER2 receptor. Docking analysis showed binding energies of -7.56 kcal/mol for mitragynine and -8.77 kcal/mol for⁣ 7-OH, with interactions observed⁤ at key residues such as Leu726, Val734, Ala751, Lys753, Thr798, and Asp863. These results suggest that both compounds could effectively ‌occupy HER2’s active site,possibly disrupting oncogenic signaling pathways.​ Molecular dynamics simulations confirmed the stability of complexes involving mitragynine, 7-OH, and a ‌native HER2 ligand over⁤ the simulation period.

Further validation using the MM-PBSA method supported these ‌findings. While​ the native HER2 ligand⁤ exhibited the strongest binding,mitragynine and ​7-OH showed moderately strong affinities. Importantly, both compounds satisfied multiple drug-likeness rules (Lipinski, Ghose, Veber,​ and Egan) and demonstrated favorable ADMET properties, ​indicating their potential as lead compounds for further preclinical inquiry.

This research aligns with a ​growing body of work exploring the potential of natural compounds in cancer treatment. These compounds offer a potentially less toxic and ⁤more accessible alternative to traditional chemotherapy. While further ​research is needed, these findings offer a promising new avenue for developing more effective treatments for HER2-positive breast cancer.